Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT01486888
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1155
- Registration Number
- NCT01486875
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Lund, Sweden
Special Survey for Type 1 or Type 2 Diabetic Patients
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1463
- Registration Number
- NCT01487408
Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy
Completed
- Conditions
- Hormone Replacement Therapy, Post-MenopausalMenopause
- Interventions
- Drug: Marketed low dose hormone replacement therapy
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3760
- Registration Number
- NCT01487304
- Locations
- 🇨🇿
Novo Nordisk Investigational Site, Prague, Czech Republic
Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis
Phase 1
Completed
- Conditions
- MenopausePostmenopausal Vaginal Atrophy
- Interventions
- Drug: estradiol, 10 mcgDrug: estradiol, 25 mcg
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01486979
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neu-Ulm, Germany
Bioequivalence of Two Insulatard® Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: isophane human insulin
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT01486901
Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 170
- Registration Number
- NCT01487798
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01487811
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Special Survey of Production of Insulin Aspart Specific Antibody
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 204
- Registration Number
- NCT01487369
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01486381
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
© Copyright 2025. All Rights Reserved by MedPath